Drugs for Myopia (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):
(show top 50)
(show all 161)
# |
|
Name |
Status |
Phase |
Clinical Trials |
Cas Number |
PubChem Id |
1 |
|
Loteprednol etabonate |
Approved, Experimental |
Phase 4 |
|
82034-46-6, 129260-79-3 |
22227703 9865442 444025 |
Synonyms:
17-Ethoxycarbonyloxy-11-hydroxy-3-oxoandrosta-1,4-diene-17-carboxylate, chloromethyl
AIREX
Alrex
CDDD-5604
CEHOAC
Chloromethyl 17 ethoxycarbonyloxy 11 hydroxy 3 oxoandrosta 1,4 diene 17 carboxylate
Chloromethyl 17-ethoxycarbonyloxy-11-hydroxy-3-oxoandrosta-1,4-diene-17-carboxylate
Etabonate, loteprednol
HGP-1
|
INVELTYS
KPI-121
Lotemax
LOTEMAX SM
Loteprednol
Loteprednol etabonate
Loteprednol etabonic acid
P-5604
|
|
2 |
|
Fluorometholone |
Approved, Investigational |
Phase 4 |
|
426-13-1 |
9878 |
Synonyms:
(1R,2S,8S,10S,11S,14R,15S,17S)-14-ACETYL-1-FLUORO-14,17-DIHYDROXY-2,8,15-TRIMETHYLTETRACYCLO[8.7.0.02,7.011,15]HEPTADECA-3,6-DIEN-5-ONE
9-Fluoro-11b,17-dihydroxy-6a-methylpregna-1,4-diene-3,20-dione
9-Fluoro-11beta,17-dihydroxy-6alpha-methylpregna-1,4-diene-3,20-dione
9-Fluoro-11β,17-dihydroxy-6α-methylpregna-1,4-diene-3,20-dione
Alcon brand OF fluorometholone
Allergan brand 1 OF fluorometholone
Allergan brand 2 OF fluorometholone
Allergan brand 3 OF fluorometholone
Cortisdin
Efflumidex
FLAREX
Flarex®|FML®
FLP469
FLUATON
Flucon
Flucon, isopto
Fluor OP
Fluormetholon
Fluormetholone
Fluoro ophtal
Fluoromethalone
Fluorometholon
FLUOROMETHOLONE
FLUOROMÉTHOLONE
|
Fluorometholonum
Fluorometolona
Fluoro-ophtal
Fluor-OP
Fluoropos
Fml
FML Forte
FML FTE
FML Liquifilm
FML-NEO
Isdin brand OF fluorometholone
Isopto flucon
Novartis brand OF fluorometholone
NSC 33001
NSC-33001
Oxylone
Pharm allergan brand OF fluorometholone
Pharm-allergan brand OF fluorometholone
Pharmascience brand OF fluorometholone
PMS Fluorometholone
PMS-Fluorometholone
Ursapharm brand OF fluorometholone
Winzer brand OF fluorometholone
|
|
3 |
|
Bevacizumab |
Approved, Investigational |
Phase 4 |
|
216974-75-3 |
135329020 |
Synonyms:
12-IGG1
ANTIVEGF
Anti-VEGF Humanized Monoclonal Antibody
Anti-VEGF monoclonal antibody
AVA-1
AVASTIN
Bevacizumab
BEVACIZUMAB BETA
bevacizumab-awwb
|
BI 695502
BS-503A
FKB-238
HLX04
HLX-04
R-435
RG-435
RHUMAB-
rhuMAb-VEGF
|
|
4 |
|
Ketorolac |
Approved |
Phase 4 |
|
74103-06-3, 66635-83-4 |
3826 |
Synonyms:
(+-)-5-Benzoyl-2,3-dihydro-1H-pyrrolizine-1-carboxylate
(+-)-5-Benzoyl-2,3-dihydro-1H-pyrrolizine-1-carboxylic acid
(+-)-Ketorolac
ACULAR
Acular LS
Acular Preservative Free
Acular®|Toradol®
Ketoralac
Ketorolac
|
Kétorolac
Ketorolac tromethamine
Ketorolaco
Ketorolaco [Spanish]
Ketorolacum
Ketorolacum [Latin]
rac-Ketorolac
Toradol
|
|
5 |
|
Povidone-iodine |
Approved |
Phase 4 |
|
25655-41-8 |
|
Synonyms:
Iodopovidone
Povidone iodine
Povidone, iodinated
|
|
|
6 |
|
Iodine |
Approved, Investigational |
Phase 4 |
|
7553-56-2 |
807 |
Synonyms:
Cadex
Diiodine
I2
Iode
Iodine
Iodine 127
Iodine-127
Iodine-molecule
|
Iodio
iodo
Iodum
Jod
Jood
Molecular iodine
NSC-42355
Tincture iodine
|
|
7 |
|
Povidone K30 |
Approved, Experimental, Withdrawn |
Phase 4 |
|
9003-39-8 |
6917 131751496 |
Synonyms:
1-Ethenyl-2-pyrrolidinone
1-Ethenyl-2-pyrrolidinone (9ci)
1-Ethenyl-2-pyrrolidinone homopolymer
1-Ethenyl-2-pyrrolidinone homopolymer, 9ci
1-Ethenyl-2-pyrrolidinone polymers
1-Ethenyl-2-pyrrolidinone, homopolymer
1-Vinyl-2-pyrrolidinone
1-Vinyl-2-pyrrolidinone cross-linked insoluble polymer
1-Vinyl-2-pyrrolidinone homopolymer
1-Vinyl-2-pyrrolidinone polymer
1-Vinyl-2-pyrrolidinone, monomer
1-Vinyl-2-pyrrolidinone, polymer
1-Vinyl-2-pyrrolidone
1-Vinyl-2-pyrrolidone polymer
1-Vinylpyrrolidin-2-one
1-vinylpyrrolidin-2-one homopolymer
1-Vinylpyrrolidinone
1-Vinylpyrrolidone
2-Pyrrolidinone, 1-ethenyl, homopolymer
2-Pyrrolidinone, 1-ethenyl-, homopolymer
2-Pyrrolidinone, 1-vinyl-, polymers
Agent at 717
Agent at-717
Agrimer
Albigen a
Aldacol Q
Alphadine
Alphadines
Antaron P 804
Arufil
Betadine
Betadines
Betaisodona
Betaisodonas
Bolinan
Bolinan 40
Crospovidone
Disadine
Disadines
Dulcilarme
Dulcilarmes
Duratears free
Enterode
Enterodes
Enterodez
Ganex P 804
Ganex P-804
Hemodesis
Hemodez
Huntington laboratories brand OF povidone iodine
Huntington laboratories brand OF povidone-iodine
Hypotear
Hypotears
Isodine
Isodines
K 115 (Polyamide)
K 25
K 25 (Polymer)
K 30
K 30 (Polymer)
K 60
K 60 (Polymer)
K115 (Polyamide)
K25 (Polymer)
K30 (Polymer)
K60 (Polymer)
Kollidin CLM
Kollidon
Kollidon 17
Kollidon 25
'Kollidon 25'
Kollidon 30
Kollidon CL
Lacophtal
Lacri-stulln
Lagrifilm
Liquifilm lagrimas
Luviskol
Luviskol K 30
Luviskol K 90
Luviskol K30
Luviskol K-30
Luviskol K90
N- Vinyl pyrrolidone
Neocompensan
Nutrivisc
N-Vinyl pyrrolidone
N-Vinyl-2-pyrrolidinone
N-Vinyl-2-pyrrolidone
N-Vinyl-2-pyrrolidone polymer
N-Vinylbutyrolactam polymer
N-Vinylpyrrolidinone
N-Vinylpyrrolidinone polymer
N-Vinylpyrrolidone
N-Vinylpyrrolidone polymer
N-Vinylpyrrolidone-2
Oculotect
Peragal ST
Peregal ST
Periston
Periston-N
Peviston
Pharmadine
Pharmadines
'plasdone'
Plasdone
Plasdone 4
Plasdone K 29-32
Plasdone K-26/28
Plasdone K29/32
Plasdone K29-32
|
Plasdone no. 4
Plasdone XL
Plasmosan
Polividone
Polvidone
Poly(1-(2-oxo-1-pyrrolidinyl)-1,2-ethanediyl)
Poly(1-(2-oxo-1-pyrrolidinyl)ethylene)
Poly(1-ethenyl-2-pyrrolidinone)
Poly(1-vinyl-2-pyrrolidinone)
Poly(1-vinyl-2-pyrrolidinone) homopolymer
Poly(1-vinyl-2-pyrrolidinone) hueper's polymer no.1
Poly(1-vinyl-2-pyrrolidinone) hueper's polymer no.2
Poly(1-vinyl-2-pyrrolidinone) hueper's polymer no.3
Poly(1-vinyl-2-pyrrolidinone) hueper's polymer no.4
Poly(1-vinyl-2-pyrrolidinone) hueper's polymer no.5
Poly(1-vinyl-2-pyrrolidinone) hueper's polymer no.6
Poly(1-vinyl-2-pyrrolidinone) hueper's polymer no.7
Poly(1-vinyl-2-pyrrolidone)
Poly(1-vinylpyrrolidinone)
Poly(N-vinyl-2-pyrrolidinone)
Poly(N-vinyl-2-pyrrolidone)
Poly(N-vinylbutyrolactam)
Poly(N-vinylpyrrolidinone)
Poly(N-vinylpyrrolidone)
Poly(vinylpolypyrrolidone)
Poly(vinylpyrrolidinone)
Poly(vinylpyrrolidone)
Polyclar a. t
Polyclar a. t.
Polyclar at
Polyclar H
Polyclar L
Polyclar-at
Polygyl
Poly-N-vinyl pyrrolidone
Poly-N-vinylpyrrolidone
Polyplasdone
Polyplasdone XL
Polyvidon
Polyvidons
Polyvidonum
Polyvinyl pyrrolidone
Polyvinylpolypyrrolidone
Polyvinylpyrrolidone
Polyvinylpyrrolidone iodine
Polyvinylpyrrolidone iodines
Polyvinylpyrrolidone K 30
Polyvinylpyrrolidone K-29/32
Polyvinylpyrrolidone K30
Polyvinylpyrrolidone polymers
Polyvinylpyrrolidone, cross-linked
Povidona
Povidone
Povidone iodine
Povidone K29/32
Povidone K29-32
Povidone(usan)
Povidone, ban, usan
Povidone, unspecified
Povidone-iodine
Povidone-iodines
Povidonum
Protagen
Protagens
Protagent
Providine
Providines
PVP 1
PVP 2
PVP 3
PVP 4
PVP 40
PVP 5
PVP 6
PVP 7
PVP Iodine
PVP K 3
PVP K30
PVP K-30
PVP10_SIAL
PVP40_SIAL
PVP-I
PVP-Iodine
PVP-Iodines
PVP-K 15
PVP-K 3
PVP-K 30
PVP-K 60
PVP-K 90
PVPP
Refresh
Sauflon
Soothe
Subtosan
Tears plus
Tolpovidone I 131
Tolpovidone I-131
Toxobin
Unifluid
Unspecified povidone
Vidirakt S mit PVP
Vidisic PVP ophtiole
Vinisil
Vinyl-2-pyrrolidone
Vinylbutyrolactam
Vinylpyrrolidinone
Vinylpyrrolidinone polymer
Vinylpyrrolidone
Vinylpyrrolidone polymer
V-Pyrol
Wet-comod
|
|
8 |
|
Levofloxacin |
Approved, Investigational |
Phase 4 |
|
100986-85-4 |
149096 |
Synonyms:
(-)-Ofloxacin
(2S)-7-FLUORO-2-METHYL-6-(4-METHYLPIPERAZIN-1-YL)-10-OXO-4-OXA-1-AZATRICYCLO[7.3.1.0^{5,13}]TRIDECA-5(13),6,8,11-TETRAENE-11-CARBOXYLIC ACID
(3S)-(-)-9-Fluoro-3-methyl-10-(4-methyl-1-piperazinyl)-7-oxo-2,3-dihydro-7H-pyrido[1,2,3-de][1,4]benzoxazine-6-carboxylate
(3S)-(-)-9-Fluoro-3-methyl-10-(4-methyl-1-piperazinyl)-7-oxo-2,3-dihydro-7H-pyrido[1,2,3-de][1,4]benzoxazine-6-carboxylic acid
(S)-(-)-9-Fluoro-3-methyl-10-(4-methyl-1-piperazinyl)-7-oxo-2,3-dihydro-7H-pyrido[1,2,3-de][1,4]benzooxazine-6-carboxylate
(S)-(-)-9-Fluoro-3-methyl-10-(4-methyl-1-piperazinyl)-7-oxo-2,3-dihydro-7H-pyrido[1,2,3-de][1,4]benzooxazine-6-carboxylic acid
(S)-9-Fluoro-2,3-dihydro-3-methyl-10-(4-methyl-1-piperazinyl)-7-oxo-7H-pyrido(1,2,3-de)-1,4-benzoxazine-6-carboxylate
(S)-9-Fluoro-2,3-dihydro-3-methyl-10-(4-methyl-1-piperazinyl)-7-oxo-7H-pyrido(1,2,3-de)-1,4-benzoxazine-6-carboxylic acid
(S)-Ofloxacin
Anhydrous, levofloxacin
Cravit
DR-3355
EVOXIL
FLOXACIN
Floxin
IQUIX
Levaquin
|
LEVOFLOXACIN
Levofloxacin anhydrous
LEVOFLOXACIN HEMIHYDRATE
Levofloxacin hydrate
Levofloxacine
Levofloxacino
Levofloxacinum
L-Ofloxacin
Ofloxacin
Ofloxacin S-(-)-form
OFLOXACIN S-(-)-FORM HEMIHYDRATE
Ofloxacin, (S)-isomer
OFTAQUIX
QUINSAIR
Quixin
RWJ-25213
TAVANIC
|
|
9 |
|
Ofloxacin |
Approved |
Phase 4 |
|
82419-36-1 |
4583 |
Synonyms:
8-Fluoro-3-methyl-9-(4-methyl-piperazin-1-yl)-6-oxo-2,3-dihydro-6H-1-oxa-3a-aza-phenalene-5-carboxylate
8-Fluoro-3-methyl-9-(4-methyl-piperazin-1-yl)-6-oxo-2,3-dihydro-6H-1-oxa-3a-aza-phenalene-5-carboxylic acid
Akilen
Baccidal
Bactocin
Danoflox
DL-8280
Effexin
EXOCIN
Exocine
Flobacin
Flodemex
Flotavid
Flovid
Floxal
Floxil
Floxin
FLOXIN OTIC
Floxstat
Fugacin
Hoe 280
Hoe-280
Inoflox
J01MA01
Kinflocin
Kinoxacin
Liflox
Loxinter
Marfloxacin
Medofloxine
Mergexin
Novecin
Nufafloqo
Obide
Occidal
OCUFLOX
Ofcin
Oflin
Oflocee
Oflocet
|
Oflocin
Oflodal
Oflodex
Oflodura
Oflox
O-Flox
OFLOXACIN
Ofloxacin hydrochloride
Ofloxacine
Ofloxacino
Ofloxacinum
Ofloxin
OFLX
Ofus
Onexacin
Operan
Orocin
Otonil
Pharflox
Praxin
Puiritol
Qinolon
Qipro
Quinolon
Quotavil
Rilox
Sinflo
Tabrin
Taravid
Tariflox
Tarivid
TARIVID 400
TARIVID I.V.
Telbit
Tructum
Uro Tarivid
Viotisone
VISIREN
Zanocin
|
|
10 |
|
Nepafenac |
Approved, Investigational |
Phase 4 |
|
78281-72-8 |
151075 |
Synonyms:
2-Amino-3-benzoylbenzeneacetamide
AHR 9434
AHR-9434
AL 6515
AL-6515
Amfenac amide
|
ILEVRO
Nepafenac
Népafénac
Nepafenaco
Nepafenacum
Nevanac
|
|
11 |
|
Propoxycaine |
Approved |
Phase 4 |
|
86-43-1 |
6843 |
Synonyms:
2-(Diethylamino)ethyl 4-amino-2-propoxybenzoic acid
Hydrochloride, propoxycaine
PROPOXYCAINE
|
Propoxycaine hydrochloride
Propoxyprocaine
|
|
12 |
|
Dipivefrin |
Approved |
Phase 4 |
|
52365-63-6 |
3105 |
Synonyms:
(+-)-4-[1-Hydroxy-2-(methylamino)ethyl]-O-phenylene divavalate
(+-)-4-[1-Hydroxy-2-(methylamino)ethyl]-O-phenylene divavalic acid
(±)-4-[1-hydroxy-2-(methylamino)ethyl]-o-phenylene divavalate
1-(3',4'-Dipivaloyloxyphenyl)-2-methylamino-1-ethanol
4-[1-Hydroxy-2-(methylamino)ethyl]-O-phenylene divavalate
4-[1-Hydroxy-2-(methylamino)ethyl]-O-phenylene divavalic acid
Adrenaline dipivalate
Alcon brand OF dipivefrin hydrochloride
Allergan brand OF dipivefrin hydrochloride
Apo-dipivefrin
Apotex brand OF dipivefrin hydrochloride
D Epifrin
Diopine
Dipivaloylepinephrine
Dipivalyl epinephrine
Dipivefrin
Dipivefrin acetate, (+-)-isomer
Dipivefrin citrate (1:1), (+-)-isomer
Dipivefrin hydrochloride
Dipivefrin hydrochloride, (+-)-isomer
Dipivefrin monophosphate, (+-)-isomer
Dipivefrin monosulfate, (+-)-isomer
|
Dipivefrin nitrate, (+-)-isomer
Dipivefrin perchlorate
Dipivefrin propanoate, (+-)-isomer
Dipivefrin tartrate (1:1), (+-)-(R-(r*,r*))-isomer
Dipivefrin tartrate (1:1), (R)-(R-(r*,r*))-isomer
Dipivefrin, (R)-isomer
Dipivefrina
Dipivefrine
Dipivéfrine
Dipivefrinum
Dipoquin
DPE
Glaucothil
Glaudrops
Ioquin brand OF dipivefrin hydrochloride
Pharm-allergan brand OF dipivefrin hydrochloride
Pharmascience brand OF dipivefrin hydrochloride
PMS-Dipivefrin
PRO-EPINEPHRINE
Propine
Ratio-dipivefrin
Ratiopharm brand OF dipivefrin hydrochloride
|
|
13 |
|
Atropine |
Approved, Vet_approved |
Phase 4 |
|
101-31-5, 5908-99-6, 51-55-8 |
3661 154417 174174 |
Synonyms:
(-)-Atropine
(−)-ATROPINE
(-)-Hyoscyamine
(−)-HYOSCYAMINE
(±)-atropine
(±)-hyoscyamine
(Leo)-atropine
(Leo)-hyoscyamine
(S)-(-)-Hyoscyamine
(S)-(−)-HYOSCYAMINE
(S)-(Leo)-hyoscyamine
(S)Atropine
(S)-ATROPINE
[3(S)-endo]-a-(Hydroxymethyl)benzeneacetate 8-methyl-8-azabicyclo[3.2.1]oct-3-yl ester
[3(S)-endo]-a-(Hydroxymethyl)benzeneacetic acid 8-methyl-8-azabicyclo[3.2.1]oct-3-yl ester
[3(S)-endo]-alpha-(Hydroxymethyl)benzeneacetate 8-methyl-8-azabicyclo[3.2.1]oct-3-yl ester
[3(S)-endo]-alpha-(Hydroxymethyl)benzeneacetic acid 8-methyl-8-azabicyclo[3.2.1]oct-3-yl ester
[3(S)-endo]-Α-(hydroxymethyl)benzeneacetate 8-methyl-8-azabicyclo[3.2.1]oct-3-yl ester
[3(S)-endo]-Α-(hydroxymethyl)benzeneacetic acid 8-methyl-8-azabicyclo[3.2.1]oct-3-yl ester
Anaspaz
ATROJECT
ATROPEN
Atropen®|hyoscyamine
ATROPHATE
Atropin
Atropina
ATROPINE
ATROPINE (AUTOINJECTOR)
Atropine sulfate, 3(S)-endo-isomer
Atropine, 3(S)-endo-isomer
Atropinum
BUWECON
CYSTOSPAZ
Cytospaz
|
DATURIN
Daturine
dl-Hyoscyamine
dl-tropyltropate
DONNAMAR
Duboisine
EGAZIL
Hyocyamine
HYOMAX
HYOSCYAMIN
Hyoscyamine
Hyoscyamine hydrobromide
Hyoscyamine hydrochloride
Hyoscyamine sulfate
Hyoscyamine sulfate anhydrous
HYOSCYAMINUM
ISOPTO ATROPINE
L-Atropine
LEVBID
LEVSIN
LEVSINEX
L-Hyopscyamine
L-Hyoscamine
L-Hyoscyamine
L-Tropine tropate
L-Tropine tropic acid
NEOQUESS
NULEV
SPACOL T/S
SYMAX
Tropine tropate
Tropine, (-)-tropate
Tropine, (-)-tropic acid
TROPINE-L-TROPATE
|
|
14 |
|
Tropicamide |
Approved, Investigational |
Phase 4 |
|
1508-75-4 |
5593 |
Synonyms:
Akorn brand OF tropicamide
Alcon brand OF tropicamide
Bournonville brand OF tropicamide
Cahill may roberts brand OF tropicamide
Chauvin brand OF tropicamide
Colircusi tropicamida
Medical ophthalmics brand OF tropicamide
Minims tropicamide
MYD947
Mydral
Mydriacyl
Mydriacyl®
Mydriafair
Mydriaticum
Mydrum
N-Ethyl-alpha-(hydroxymethyl)-N-(4-pyridinylmethyl)benzeneacetamide
N-Ethyl-N-(4-pyridylmethyl)tropamide
NODS
Novartis brand OF tropicamide
Ocu tropic
Ocumed brand OF tropicamide
Ocusoft brand OF tropicamide
Ocu-tropic
OcuTropic
Pharmafair brand OF tropicamide
|
Rivex brand OF tropicamide
RO-1-7683
Stulln brand 1 OF tropicamide
Stulln brand 2 OF tropicamide
Triaminic DM
Tropicacyl
TROPICAMID
TROPICAMIDA
TROPICAMIDE
Tropicamide alcon brand
Tropicamide chauvin brand
Tropicamide faure
Tropicamide minims
Tropicamide monofree
Tropicamide monohydrochloride, (R)-isomer
Tropicamide monohydrochloride, (S)-isomer
Tropicamide novartis brand
Tropicamide ocumed brand
Tropicamide pharmafair brand
Tropicamide rivex brand
Tropicamide, (+-)-isomer
Tropicamide, (R)-isomer
Tropicamide, (S)-isomer
TROPICAMIDUM
|
|
15 |
|
Mitomycin |
Approved |
Phase 4 |
|
50-07-7 |
5746 |
Synonyms:
7-Amino-9alpha-methoxymitosane
7-Amino-9a-methoxymitosane
7-Amino-9α-methoxymitosane
Ametycine
Mitamycin
Mitocin C
MitocinC
Mitocin-C
Mitomycin
|
Mitomycin C
Mitomycin-C
MITOSOL
MITOZYTREX
MMC
Muamycin
Mutamycin
MYTOZYTREX
NSC-26980
|
|
16 |
|
Cadexomer iodine |
Experimental |
Phase 4 |
|
94820-09-4 |
|
Synonyms:
|
17 |
|
Anti-Allergic Agents |
|
Phase 4 |
|
|
|
18 |
|
Vitamins |
|
Phase 4 |
|
|
|
19 |
|
Cathartics |
|
Phase 4 |
|
|
|
20 |
|
Carboxymethylcellulose Sodium |
|
Phase 4 |
|
|
|
21 |
|
Echothiophate Iodide |
|
Phase 4 |
|
|
|
Synonyms:
217-MI
ECHOTHIOPHATE IODIDE
ECOSTIGMINE IODIDE
|
ECOTHIOPATE IODIDE
PHOSPHOLINE IODIDE
|
|
22 |
|
Laxatives |
|
Phase 4 |
|
|
|
23 |
|
Cholinesterase Inhibitors |
|
Phase 4 |
|
|
|
24 |
|
Omega 3 Fatty Acid |
|
Phase 4 |
|
|
|
25 |
|
Pharmaceutical Solutions |
|
Phase 4 |
|
|
|
26 |
|
Lubricant Eye Drops |
|
Phase 4 |
|
|
|
27 |
|
Antirheumatic Agents |
|
Phase 4 |
|
|
|
28 |
|
Ketorolac Tromethamine |
|
Phase 4 |
|
|
|
Synonyms:
ACULAR
ACULAR LS
ACULAR PRESERVATIVE FREE
ACUVAIL
|
KETOROLAC TROMETHAMINE
SPRIX
TORADOL
|
|
29 |
|
Cyclooxygenase Inhibitors |
|
Phase 4 |
|
|
|
30 |
|
Anti-Inflammatory Agents, Non-Steroidal |
|
Phase 4 |
|
|
|
31 |
|
Anesthetics, Local |
|
Phase 4 |
|
|
|
32 |
|
Proxymetacaine |
|
Phase 4 |
|
|
|
33 |
|
Neurotransmitter Agents |
|
Phase 4 |
|
|
|
34 |
|
Bronchodilator Agents |
|
Phase 4 |
|
|
|
35 |
|
Parasympatholytics |
|
Phase 4 |
|
|
|
36 |
|
Anti-Asthmatic Agents |
|
Phase 4 |
|
|
|
37 |
|
Anti-Arrhythmia Agents |
|
Phase 4 |
|
|
|
38 |
|
Ophthalmic Solutions |
|
Phase 4 |
|
|
|
39 |
|
Respiratory System Agents |
|
Phase 4 |
|
|
|
40 |
|
Mydriatics |
|
Phase 4 |
|
|
|
41 |
|
Muscarinic Antagonists |
|
Phase 4 |
|
|
|
42 |
|
Cholinergic Antagonists |
|
Phase 4 |
|
|
|
43 |
|
Cholinergic Agents |
|
Phase 4 |
|
|
|
44 |
|
Anti-Bacterial Agents |
|
Phase 4 |
|
|
|
45 |
|
Alkylating Agents |
|
Phase 4 |
|
|
|
46 |
|
Antibiotics, Antitubercular |
|
Phase 4 |
|
|
|
47 |
|
Moxifloxacin |
Approved, Investigational |
Phase 2, Phase 3 |
|
186826-86-8, 354812-41-2, 151096-09-2 |
152946 |
Synonyms:
1-Cyclopropyl-6-fluoro-1,4-dihydro-8-methoxy-7-((4as,7as)-octahydro-6H-pyrrolo(3,4-b)pyridin-6-yl)-4-oxo-3-quinolinecarboxylate
1-Cyclopropyl-6-fluoro-1,4-dihydro-8-methoxy-7-((4as,7as)-octahydro-6H-pyrrolo(3,4-b)pyridin-6-yl)-4-oxo-3-quinolinecarboxylic acid
1-Cyclopropyl--7-(2,8-diazabicyclo(4.3.0)non-8-yl)-6-fluoro-8-methoxy-1,4-dihydro-4-oxo-3-quinolinecarboxylic acid
Actira
Avalox
Avelox
AVELOX I.V.
BAY 12-8039
|
Izilox
MOXIFLOXACIN
Moxifloxacin HCl
Moxifloxacin hydrochloride
Moxifloxacino
Octegra
Proflox
VIGAMOX
|
|
48 |
|
Pilocarpine |
Approved, Investigational |
Phase 3 |
|
54-71-7, 92-13-7 |
4819 5910 |
Synonyms:
(+)-PILOCARPINE
(3S,4R)-3-Ethyldihydro-4-((1-methyl-1H-imidazol-5-yl)methyl)-2(3H)-furanone
(3S-cis)-3-Ethyldihydro-4-[(1-methyl-1H-imidazol-5-yl)methyl]-2(3H)-furanone
Adsorbocarpine
beta-Pilocarpine hydrochloride
Hydrochloride, pilocarpine
Isopilocarpine
Isoptocarpine
Nitrate, pilocarpine
Ocusert
OCUSERT PILO
Ocusert pilo-20
OCUSERT PILO-40
Pilocarpin
Pilocarpina
|
Pilocarpine
Pilocarpine chloride
Pilocarpine HCL
Pilocarpine hydrochloride
pilocarpine hydrochloride|pilocarpine nitrate|pilokarpin|Salagen®|Vuity® (pilocarpine HCI ophthalmic solution)
Pilocarpine monohydrochloride
Pilocarpine mononitrate, (3S-cis)-isomer
Pilocarpine muriate
Pilocarpine nitrate
Pilocarpine, monohydrochloride, (3S-cis)-isomer
Pilokarpin
Pilokarpin monohydrochloride
Salagen
Spersacarpine
Spersacarpine hydrochloride
|
|
49 |
|
Tobramycin, Dexamethasone Drug Combination |
|
Phase 2, Phase 3 |
|
|
|
50 |
|
Norgestimate, ethinyl estradiol drug combination |
|
Phase 2, Phase 3 |
|
|
|
Interventional clinical trials:
(show top 50)
(show all 866)
# |
Name |
Status |
NCT ID |
Phase |
Drugs |
1 |
Comparison of Next Generation Laser Techniques of Myopia Correction: iDesign vs. SMILE |
Unknown status |
NCT03001401 |
Phase 4 |
|
2 |
Pilot Study of Prevention Myopia in Children With Low Concentration of Atropine |
Unknown status |
NCT00541177 |
Phase 4 |
atropine;tropicamide |
3 |
Randomized, Single Blinded Controlled Trial for Evaluation of the Safety and Efficacy of Loteprednol Versus Fluorometholone After Photorefractive Keratectomy for the Correction of Mild to Moderate Myopia, 3- Month Follow-up Study |
Unknown status |
NCT02974387 |
Phase 4 |
Fluorometholone(FML);Loteprednol (Lotemax) |
4 |
Echothiophate Iodide for the Prevention of Progression of Myopia |
Unknown status |
NCT02544529 |
Phase 4 |
Echothiophate Iodide 0.03% Ophthalmic Solution;Carboxymethylcellulose Sodium (0.5%) |
5 |
Atropine for Children and Adolescent Myopia Progression Study (ACAMP) |
Unknown status |
NCT03949101 |
Phase 4 |
Atropine Sulfate 1 % Ophthalmic Ointment and Atropine Sulfate 0.01% Eye Drop;atropine 0.01% eye drop |
6 |
A Prospective, Randomized, Multi Center Clinical Comparison Of Fellow Eyes Undergoing Lasik Using The Amo/Visx Customvueâ„¢ , The Bausch And Lomb Zyoptix And Planoscan And The Wavelight Allegretto Waveâ„¢ Wavefront Guided And Wavefront Optimized Excimer Laser Systems |
Unknown status |
NCT00770094 |
Phase 4 |
|
7 |
A Prospective Safety and Effectiveness Study of the 500 Hz Technolas Perfect Vision Excimer Laser in Asian Eyes Using LASIK |
Unknown status |
NCT01977807 |
Phase 4 |
|
8 |
A Prospective Safety and Effectiveness Study of a New High Repetition Rate Excimer Laser Using LASIK for the Correction of Ammetropia and Presbyopia |
Unknown status |
NCT02112968 |
Phase 4 |
|
9 |
A Prospective Safety and Effectiveness Study of the 500 Hz Technolas Perfect Vision Excimer Laser Using LASIK |
Unknown status |
NCT02071576 |
Phase 4 |
|
10 |
Ranibizumabe Intravitreal Injection for Myopic Choroidal Neovascularization |
Unknown status |
NCT01246089 |
Phase 4 |
ranibizumab injection |
11 |
A Prospective Study to Evaluate the Raindrop Near Vision Inlay in Presbyopes Implanted Under a Corneal Flap or Within a Small-Incision Pocket |
Unknown status |
NCT03376412 |
Phase 4 |
|
12 |
A Prospective Study to Evaluate the Raindrop Near Vision Inlay in Presbyopic Patients With Treatments to Optimize the Ocular Surface Before Implantation |
Unknown status |
NCT03126877 |
Phase 4 |
Mitomycin C |
13 |
A Prospective Study to Evaluate the Raindrop Near Vision Inlay in Presbyopes Treated With Mitomycin C During Surgery and Extended Steroid After Surgery |
Unknown status |
NCT03242317 |
Phase 4 |
Mitomycin C |
14 |
Aflibercept Intravitreal Injection for Myopic Choroidal Neovascularization |
Unknown status |
NCT02033018 |
Phase 4 |
Aflibercept Injection |
15 |
Dosing Strategy of Intravitreal Ranibizumab for Myopia Choroidal Neovascularization: a Single Center Randomized Prospective Study |
Completed |
NCT03042871 |
Phase 4 |
0.5mg intravitreal ranibizumab |
16 |
A Prospective, Randomised Trial of Photo-Refractive Keratectomy (PRK) and Laser-in-Situ-Keratomileusis (LASIK) for Correction of Myopia |
Completed |
NCT00404105 |
Phase 4 |
|
17 |
Evaluation of the Prophylactic Use of Mitomycin C 0.02% to Inhibit Haze Formation After Photorefractive Keratectomy for High Myopia: 15 x 30 Seconds |
Completed |
NCT00564213 |
Phase 4 |
PRK and a single intraoperative topical application of mitomycin C 0.02% for 15 seconds |
18 |
SD-OCT-guided Intravitreal Ranibizumab Treatment in Choroidal Neovascularization Due to Myopia |
Completed |
NCT03409250 |
Phase 4 |
Ranibizumab, Lucentis |
19 |
Effect of Orthokeratology on Myopia Progression in Chinese Children |
Completed |
NCT02186184 |
Phase 4 |
|
20 |
Product Performance of Bausch & Lomb PureVision® Contact Lens When Compared to Johnson & Johnson Acuvue Oasys Contact Lens and the Ciba Vision O2Optix Contact Lens Worn Daily. |
Completed |
NCT00640341 |
Phase 4 |
|
21 |
On-Eye Optical Quality of Lotrafilcon B Lenses Over 12 Hours |
Completed |
NCT03881670 |
Phase 4 |
|
22 |
A Single Center Prospective Evaluation of the Post-LASIK Flap Thickness of the FS200 Femtosecond Laser Flap |
Completed |
NCT01693939 |
Phase 4 |
|
23 |
A Prospective, Multi Center Clinical Comparison of Fellow Eyes Undergoing Lasik Using the Wavelight Allegretto Waveâ„¢ Excimer Laser in One Eye and the Amo/Visx Customvueâ„¢ or the Ladarvision 4000 Excimer Laser System in the Contralateral Eye |
Completed |
NCT00821236 |
Phase 4 |
|
24 |
Clinical Investigation of the Vision-R800 Device. Understanding the Value of High Precision Refractions and Lenses to Optometrists and Patients. Phase 2 |
Completed |
NCT04208750 |
Phase 4 |
|
25 |
Corneal and Conjunctival Sensitivity and Staining Study |
Completed |
NCT00455455 |
Phase 4 |
Optifree RepleniSH Multipurpose Disinfecting Solution;ReNu Multiplus Multipurpose Solution |
26 |
The Effects of Low Dose Atropine on Choroidal Thickness |
Completed |
NCT03544827 |
Phase 4 |
Atropine |
27 |
Infiltrative Events During Silicone Hydrogel Daily Contact Lens (Daily Wear Corneal Infiltrative Event (DWCIE) Study) |
Completed |
NCT00937105 |
Phase 4 |
|
28 |
Long-term Effects of Laser Refractive Surgery |
Completed |
NCT00350246 |
Phase 4 |
|
29 |
Effects of Contact Lens Care Regimens on the Corneal Epithelium |
Completed |
NCT00349882 |
Phase 4 |
Marketed multipurpose disinfection regimen |
30 |
Investigation of Multi-Purpose Solution-Based Corneal Staining and Ocular Comfort With Daily Wear FDA Group IV Hydrogel Lenses |
Completed |
NCT00349843 |
Phase 4 |
Marketed soft lens multipurpose disinfection regimen |
31 |
Double Masked Evaluation of Acular LS Versus Nevanac for Postoperative Pain Control in Eyes Undergoing PRK |
Completed |
NCT00347204 |
Phase 4 |
ketorolac (Acular LS);Nepafenac (Nevanac) |
32 |
Effect of Preoperative Pupil Size on Quality of Vision After Wavefront-Guided LASIK |
Completed |
NCT00889941 |
Phase 4 |
|
33 |
The Influence of Atropine on Choroidal Thickness |
Completed |
NCT03158142 |
Phase 4 |
Atropine Sulfate 1% Oph Soln |
34 |
Efficacy of PEG-400 and Systane Artificial Tears (Alcon) on Quality of Vision |
Completed |
NCT00627302 |
Phase 4 |
PEG-400;Systane |
35 |
Effect of Contact Lens Wear on Immune Cell Density and Morphology of the Ocular Surface: A Laser In Vivo Confocal Microscopy Study |
Completed |
NCT01250925 |
Phase 4 |
ReNu MultiPlus® MultiPurpose Solution;OPTI-FREE® RepleniSH®;Clear Care® |
36 |
A Prospective Study to Evaluate the Safety and Effectiveness of the Supracor Presbyopic Treatment Algorithm for Pseudophakic Eyes Using Lasik |
Completed |
NCT01387360 |
Phase 4 |
|
37 |
A Prospective Evaluation of Outcomes Following Wavefront Optimized or Wavefront Guided Lasik Procedure in Low to Moderate Myopic Patients |
Completed |
NCT01173198 |
Phase 4 |
|
38 |
A Prospective Eye to Eye Comparison of LASIK Using the Alcon Allegretto Wavefront-Guided Excimer Laser Versus AMO Visx Wavefront-Guided Excimer Laser |
Completed |
NCT01454843 |
Phase 4 |
|
39 |
Evaluation Of Visual Outcomes and Contrast Sensitivity After Myopic Wavefront-Optimized Lasik Using the 200 KHZ WAVELIGHT® FS200 Femtosecond Laser and the WAVELIGHT® ALLEGRETTO WAVE® EYE-Q Laser |
Completed |
NCT01746589 |
Phase 4 |
|
40 |
Bevacizumab Intravitreal for Myopic Choroidal Neovascularization |
Completed |
NCT00797992 |
Phase 4 |
Injection |
41 |
A Three Arm Prospective Clinical Evaluation of Three FDA-approved Intraocular Lenses Designed to Improve Distance, Intermediate and Near Vision Following Lens Extraction |
Completed |
NCT01225952 |
Phase 4 |
|
42 |
A Three Arm Prospective Clinical Evaluation of Three FDA Approved Intraocular Lenses Designed to Improve Distance, Intermediate and Near Vision Following Lens Extraction. |
Completed |
NCT01122576 |
Phase 4 |
|
43 |
Bilateral, Masked Comparison of PEG-400 Based Artificial Tear vs. Systane for Dry Eye Signs, Symptoms & Refractive Regression Associated With Myopic Laser in Situ Keratomilieusis (LASIK). |
Completed |
NCT00620893 |
Phase 4 |
PEG- 400 based artificial tear;Systane |
44 |
Multi-centered Clinical Trial on Myopia Intervention in Children and Adolescents and Establishment of a Precise Intervention Model Based on Deep Learning |
Recruiting |
NCT05357326 |
Phase 4 |
Atropine Sulfate 0.01% Eye Drop;Atropine Sulfate 0.04% Eye Drop |
45 |
Efficacy and Safety of 1% Atropine "5+3" Regimen in Children and Adolescents Controlling Myopia |
Recruiting |
NCT05448989 |
Phase 4 |
1% atropine 5+3 |
46 |
Efficacy and Safety of Anesthetic Impregnated Bandage Soft Contact Lens (BSCL) in Pain Management After Photorefractive Keratectomy (PRK). |
Recruiting |
NCT04283331 |
Phase 4 |
Proparacaine Ophthalmic |
47 |
Patient Satisfaction With Contoura Vision Topography-Guided LASIK |
Recruiting |
NCT04903301 |
Phase 4 |
|
48 |
A Prospective Randomized Comparison of the AMO CustomVue to the Alcon Wavelight in Patients Undergoing LASIK |
Active, not recruiting |
NCT02565537 |
Phase 4 |
|
49 |
Study on the Effect of Two Ways of Cycloplegia on Biological Parameters of Ciliary Muscle |
Not yet recruiting |
NCT05449015 |
Phase 4 |
1% atropine |
50 |
Improved Near Vision and Intermediate Without Loss of Binocular Distance Vision Using AGN-190584 in Subjects Utilizing Single -Use Daily, Contact Lenses for Distance Vision Correction in Both Eyes |
Not yet recruiting |
NCT05624320 |
Phase 4 |
AGN-190584 |
Cochrane evidence based reviews: myopia
|